Octreotide Interactions: Alcohol, Caffeine, Food and Other Compounds in the Published Literature

What “Interaction” Means in the Octreotide Literature

Octreotide is a synthetic analogue of the hormone somatostatin and is regulated as a prescription medicine, not as a research chemical. A 2026 review of the treatment landscape of acromegaly described somatostatin receptor ligands, including octreotide delivered by injection and in an orally administered form, as a mainstay of medical therapy in that disease and set out how they are positioned relative to surgery, radiotherapy and other drug classes (PMID 41965092). A 2017 review of somatostatin receptor ligands in acromegaly similarly described how these agents are used, including in combination with other pituitary-directed drugs, and discussed their effects on hormone secretion and on glucose metabolism (PMID 28176162).

When readers ask about “interactions,” they usually mean one of three different questions: whether a beverage such as alcohol or coffee changes how a drug behaves, whether food or fasting changes absorption, or whether two medicines given together produce an effect neither produces alone. The published octreotide literature addresses the third question far more thoroughly than the first two. This page is for educational purposes only and is not medical advice; consult a licensed physician or the prescribing clinician for any question about whether octreotide can be combined with a particular substance.

Octreotide and Alcohol

The beverage question

No controlled study in the citation set below administered ethanol alongside octreotide and measured the result. That absence should be stated plainly rather than filled in: there is no published pharmacokinetic or pharmacodynamic alcohol-challenge trial for octreotide among these papers, so any statement about what alcohol “does to” octreotide would be extrapolation rather than a reported finding.

What the literature does provide is context about the clinical settings where the two topics overlap. A 2001 review of pharmacologic therapy for portal hypertension discussed octreotide among the vasoactive agents studied for lowering portal pressure and controlling variceal bleeding in advanced liver disease (PMID 11177691). A 2019 critical review of vasoconstrictors in hepatorenal syndrome examined octreotide as part of combination regimens in patients with decompensated cirrhosis, alongside agents such as midodrine, noradrenaline and terlipressin together with albumin (PMID 31023616). Those are populations in which liver function, splanchnic circulation and volume status are already disturbed, which is why researchers treat hepatic physiology, rather than alcohol itself, as the variable they measure.

The chemistry question

“Octreotide and alcohol” also has a non-beverage meaning. Octreotide terminates in threoninol, an amino alcohol, rather than in a conventional carboxylic acid or amide, placing it in the chemical class of peptide alcohols. A 2020 methodology review surveyed the solid-phase synthesis approaches chemists use to build peptides bearing a C-terminal alcohol, including the linker and resin strategies that distinguish them from standard peptide acids (PMID 32237227). Search results mixing manufacturing chemistry with drinking questions are a common source of confusion, and the two literatures do not overlap.

Mechanistic reasoning, labeled as such

Where no interaction study exists, researchers reason from known pharmacology. That reasoning, not evidence, runs as follows: octreotide is a peptide cleared largely by peptidase activity and renal elimination rather than by the cytochrome P450 pathways that dominate most beverage-related drug interactions; ethanol, by contrast, acts on gastric emptying, splanchnic blood flow, portal pressure and glucose counter-regulation, all domains in which somatostatin analogues are also active. Overlapping physiology is a hypothesis generator, not a measured interaction, and the reviews cited here did not test it.

Octreotide and Caffeine

No study among the verified papers co-administered caffeine with octreotide or measured caffeine pharmacokinetics during somatostatin analogue therapy. The mechanistic reasoning researchers apply is again structural: caffeine is metabolised principally by hepatic CYP1A2, whereas peptide drugs such as octreotide are not conventional CYP substrates, so a classic metabolic competition is considered unlikely on first principles. That is an inference drawn from drug class, explicitly not a trial result.

The nearest adjacent evidence concerns circulatory physiology. A 2017 review of the treatment of primary orthostatic hypotension discussed octreotide among the pharmacological options evaluated for blood-pressure support in autonomic failure (PMID 28092986), and a 2025 systematic review of pharmacological interventions for orthostatic hypotension again catalogued the agents studied in that indication and the quality of the supporting trials (PMID 40951129). Both reviews describe a therapeutic area in which haemodynamic responses are the measured outcome; neither reported a caffeine-octreotide comparison.

Food, Meals and Fasting

Meals as a trigger the drug is used to address

In several indications, food is not a confounder but the clinical problem. A 2025 review of dumping syndrome after bariatric surgery set out nutritional strategies for managing symptoms provoked by meals and described integrated pharmacological management, including the role of somatostatin analogues when dietary measures prove insufficient (PMID 41097200). In that literature, meal composition and the drug are examined together by design.

Absorption and the oral route

Food matters most for absorption when a peptide is swallowed. A 2022 review of gastrointestinal permeation enhancers for oral peptide pharmaceuticals explained why peptides are poorly absorbed from the gut, enzymatic degradation and low permeability across the intestinal epithelium, and described the excipient-based enhancer technologies developed to overcome those barriers in oral peptide products (PMID 36559036). Researchers reason from that review that anything altering gastric contents, pH or transit, including a meal, is a plausible variable for an enhancer-dependent oral peptide, which is why oral peptide products carry formulation-specific administration conditions determined in their own registration studies rather than inferred from injectable data. The 2026 acromegaly review placed the oral octreotide formulation within the current therapeutic options for that condition (PMID 41965092).

Other Compounds Studied Alongside Octreotide

Most documented octreotide co-administration is deliberate combination therapy in defined clinical settings, reported in trials and reviews rather than in dedicated interaction pharmacology studies.

Receptor-level overlap with radiolabelled analogues

The most mechanistically specific overlap in this body of work involves nuclear medicine. A 2015 review of peptide receptor radionuclide therapy for neuroendocrine tumours described how radiolabelled somatostatin analogues are used to target somatostatin-receptor-expressing tumours and how receptor binding underpins both imaging and therapy (PMID 26303714). Because unlabelled and radiolabelled analogues engage the same receptor family, researchers treat scheduling between them as a pharmacological question handled by the treating nuclear medicine team, not by general interaction tables.

Oncology and palliative multi-drug settings

A 2001 review of non-surgical treatment of hepatocellular carcinoma surveyed ablative, transarterial and systemic approaches and discussed where somatostatin analogue therapy had been investigated in that disease (PMID 11685743). A 2024 prospective, open-label phase 2 study conducted at an NCI comprehensive cancer center evaluated a palliative pharmacological approach to inoperable malignant bowel obstruction, a setting in which several symptom-directed medicines are given concurrently (PMID 37769820). Both describe polypharmacy environments where combinations are chosen clinically rather than tested as isolated two-drug interactions.

Tolerability in Combination Settings: What Studies Report

The reviews in this set describe tolerability at the level of drug class rather than of specific beverage or food pairings. The 2017 somatostatin receptor ligand review discussed effects on glucose metabolism among the considerations clinicians weigh during long-term therapy in acromegaly (PMID 28176162), and the 2026 acromegaly review similarly placed tolerability alongside efficacy when comparing available medical options (PMID 41965092). In the orthostatic hypotension literature, the 2025 systematic review of pharmacological interventions assessed the evidence base for the agents used and the limitations of the available trials (PMID 40951129). None of these reports constitutes a verdict about combining octreotide with alcohol, caffeine or any supplement.

Where the Evidence Is Thin

• Alcohol: no dedicated ethanol co-administration study in the cited literature; the overlap discussed above is clinical context in liver disease (PMID 11177691).
• Caffeine: no co-administration study identified; reasoning rests on metabolic pathway differences, which is inference rather than data.
• Supplements and botanicals: not examined in any of the papers cited here.
• Food timing for injectable formulations: absorption questions in these papers concern oral peptide delivery technology generally (PMID 36559036), not meal timing for injections.

How to Read This Page

Nothing above is a recommendation, a permission, or a statement that any combination is appropriate. Octreotide is a prescription medicine whose formulation, indication and co-medication are decided by a prescribing clinician who can see the full medication list, laboratory results and diagnosis. Readers comparing sources should note which statements are findings carrying a citation and which are labelled mechanistic reasoning. A broader background on the molecule, its formulations and its studied indications is available in the PeptideU Octreotide overview.

References

• Current treatment landscape of acromegaly (The Journal of Clinical Endocrinology and Metabolism, 2026)
• Somatostatin receptor ligands in the treatment of acromegaly (Pituitary, 2017)
• Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals (Pharmaceuticals, 2022)
• Dumping Syndrome After Bariatric Surgery: Advanced Nutritional Perspectives and Integrated Pharmacological Management (Nutrients, 2025)
• Vasoconstrictors in hepatorenal syndrome - A critical review (Annals of Hepatology, 2019)
• Pharmacologic therapy for portal hypertension (Current Gastroenterology Reports, 2001)
• Nonsurgical treatment of hepatocellular carcinoma (Seminars in Oncology, 2001)
• Palliative Management of Inoperable Malignant Bowel Obstruction: Prospective, Open Label, Phase 2 Study at an NCI Comprehensive Cancer Center (Journal of Pain and Symptom Management, 2024)
• Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors (Frontiers of Hormone Research, 2015)
• The Treatment of Primary Orthostatic Hypotension (The Annals of Pharmacotherapy, 2017)
• Pharmacological Interventions for Orthostatic Hypotension: A Systematic Review (Cureus, 2025)
• Methods and Approaches for the Solid-Phase Synthesis of Peptide Alcohols (ChemPlusChem, 2020)